Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience

In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI’s in penile squamous cell carcinoma (pSCC) we performed a retrospective observation...

Full description

Bibliographic Details
Main Authors: Keren Rouvinov, Gal Mazor, Ella Kozlener, Amichay Meirovitz, Noa Shani Shrem, Omar Abu Saleh, Sondos Shalata, Alexander Yakobson, Walid Shalata
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Journal of Personalized Medicine
Subjects:
cemiplimab
penile carcinoma
chemotherapy-ineligible
squamous cell carcinoma
immune checkpoint inhibitors (ICIs)
Online Access:https://www.mdpi.com/2075-4426/13/11/1623

Internet

https://www.mdpi.com/2075-4426/13/11/1623

Similar Items